| Literature DB >> 29896155 |
Annie C H Fung1, Gary Tse1,2, Hiu Lam Cheng3, Eric S H Lau1, Andrea Luk1,2,4, Risa Ozaki1, Tammy T Y So1, Rebecca Y M Wong1, Joshua Tsoh3, Elaine Chow1, Yun Kwok Wing5, Juliana C N Chan1,2,4, Alice P S Kong1,2,4.
Abstract
BACKGROUND AND OBJECTIVES: Undiagnosed depression is an important comorbidity in type 2 diabetes (T2D) which can be detected using the Geriatric Depression Scale (GDS-15) questionnaire. In this cross-sectional study, we examined the associations of depression using GDS score with control of cardiometabolic risk factors and health status in elderly patients with T2D. SETTING AND PARTICIPANTS: Between February and December 2013, patients aged ≥65 years who underwent structured comprehensive assessment as a quality improvement program at the Diabetes Center of a teaching hospital were invited to complete the GDS-15 questionnaire. MAIN OUTCOME MEASURES: Depression was defined as a GDS score ≥7. Demographic data, prior history of co-morbidities, frequency of self-reported hypoglycemia, and attainment of treatment targets defined as HbA1c, <7%, blood pressure <130/80 mmHg, and LDL-C <2.6 mmol/L were documented.Entities:
Keywords: GDS-15; comorbidities; depression; diabetes; elderly; hypoglycaemia
Year: 2018 PMID: 29896155 PMCID: PMC5986894 DOI: 10.3389/fendo.2018.00261
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Demographic and clinical characteristics of Chinese elderly patients with type 2 diabetes with or without depression defined by Geriatric Depression Score (GDS score ≥7).
| Total | Non-depressed | Depressed | ||
|---|---|---|---|---|
| Number of subjects | 325 (100%) | 283 (87%) | 42 (13%) | – |
| Age (years) | 69 (61–77) | 69 (62–76) | 69 (60–78) | 0.679 |
| Male gender | 211 (65%) | 183 (65%) | 28 (67%) | 0.800 |
| Duration of diabetes (years) | 12.0 ± 8.3 | 11.6 ± 8.1 | 15.1 ± 9.1 | 0.020 |
| Ex or current smoker | 105 (32%) | 88 (31%) | 17 (40%) | 0.225 |
| Ex or current alcohol drinker | 133 (41%) | 114 (40%) | 19 (45%) | 0.542 |
| GDS-15 score | 3.26 ± 3.12 | 2.31 ± 1.81 | 9.71 ± 2.28 | – |
| Body mass index (kg/m2) | 25.2 ± 3.3 | 25.1 ± 3.2 | 25.7 ± 4.0 | 0.305 |
| Waist circumference, men (cm) | 92.7 ± 8.9 | 91.9 ± 8.7 | 97.9 ± 8.5 | 0.001 |
| Waist circumference, women (cm) | 87.2 ± 8.8 | 87.6 ± 8.5 | 84.0 ± 10.1 | 0.160 |
| Fasting plasma glucose (mmol/L) | 7.0 ± 2.0 | 6.9 ± 1.9 | 7.5 ± 2.7 | 0.151 |
| HbA1c (%) | 7.2 ± 1.1 | 7.2 ± 1.1 | 7.5 ± 1.0 | 0.081 |
| Total cholesterol (mmol/L) | 4.22 ± 0.81 | 4.20 ± 0.83 | 4.35 ± 0.64 | 0.277 |
| HDL-cholesterol (mmol/L) | 1.36 ± 0.38 | 1.36 ± 0.36 | 1.41 ± 0.46 | 0.386 |
| LDL-cholesterol (mmol/L) | 2.17 ± 0.73 | 2.12 ± 0.73 | 2.24 ± 0.69 | 0.514 |
| Triglyceride (mmol/L) | 1.20 (0.50–1.90) | 1.20 (0.50–1.90) | 1.20 (0.52–1.88) | 0.565 |
| Systolic blood pressure (mmHg) | 138 ± 18 | 137 ± 19 | 145 ± 17 | 0.014 |
| Diastolic blood pressure (mmHg) | 76 ± 9 | 75 ± 9 | 77 ± 9 | 0.382 |
| Frequent hypoglycemic episodes (≥1 event/month) | 25 (8%) | 18 (6%) | 7 (17%) | 0.030 |
| History of cardiovascular events | 93 (29%) | 78 (28%) | 15 (36%) | 0.275 |
| History of any co-morbidities | 168 (52%) | 137 (49%) | 31 (74%) | 0.002 |
| 0.055 | ||||
| (1) Lifestyle only | 23 (7%) | 21 (7%) | 2 (5%) | – |
| (2) On oral anti-diabetic drugs | 222 (69%) | 199 (71%) | 23 (55%) | – |
| (3) On insulin | 14 (4%) | 12 (4%) | 2 (5%) | – |
| (4) On both oral anti-diabetic drugs and insulin | 65 (20%) | 50 (18%) | 15 (36%) | – |
| On lipid-lowering drugs | 229 (71%) | 197 (70%) | 32 (76%) | 0.383 |
| On anti-hypertensive drugs | 269 (83%) | 230 (81%) | 39 (93%) | 0.064 |
| HbA1c <7.0% | 115 (48%) | 144 (51%) | 11 (26%) | 0.003 |
| LDL-cholesterol <2.6 mmol/L | 241 (75%) | 212 (75%) | 29 (69%) | 0.374 |
| Blood pressure <130/80 mmHg | 107 (33%) | 101 (36%) | 6 (14%) | 0.006 |
| No target attained | 39 (12%) | 29 (10%) | 10 (24%) | – |
| 1 Target attained | 113 (35%) | 95 (34%) | 18 (43%) | –- |
| 2 Targets attained | 129 (40%) | 115 (41%) | 14 (33%) | –- |
| All three targets attained | 44 (13%) | 44 (16%) | 0 (0%) | 0.004 |
Data presented in mean ± SD, median (interquartile range, IQR) or number (%) (missing data excluded using exclude cases pairwise on SPSS).
*denotes P-value < 0.05.
.
.
Logistic regression analysis for risk association between depression (GDS score ≥7) and control of cardiometabolic risk factors and co-morbidities in Chinese elderly patients with type 2 diabetes.
| Odds ratio (95% confidence interval) | |||
|---|---|---|---|
| Blood pressure <130/80 mmHg target attainment | Model 1 | 0.330 (0.133–0.823) | 0.017 |
| Model 2 | 0.323 (0.127–0.819) | 0.017 | |
| Model 3 | 0.301 (0.121–0.748) | 0.010 | |
| Model 4 | 0.292 (0.118–0.726) | 0.008 | |
| HbA1c <7.0% target attainment | Model 1 | 0.349 (0.168–0.724) | 0.005 |
| Model 2 | 0.441 (0.201–0.968) | 0.041 | |
| Model 3 | 0.409 (0.188–0.890) | 0.024 | |
| Model 4 | 0.400 (0.188–0.853) | 0.018 | |
| History of any co-morbidities | Model 1 | 2.844 (1.347–6.002) | 0.006 |
| Model 2 | 2.559 (1.178–5.562) | 0.018 | |
| Model 3 | 2.850 (1.349–6.021) | 0.006 | |
| Model 4 | 2.853 (1.354–6.013) | 0.006 | |
Model 1: Adjusted for age, gender and use of anti-hypertensive drugs.
Model 2: Adjusted for age, gender, use of anti-diabetic drugs, insulin, lipid lowering drugs and anti-hypertensive drugs.
Model 3: Adjusted for age, gender, use of anti-diabetic drugs, and use of insulin.
Model 4: adjusted for age, gender, and duration of diabetes.
*denotes P-value < 0.05.
.
Linear regression analysis for risk association of depression (GDS score ≥7) with control of cardiometabolic risk factors in Chinese elderly patients with type 2 diabetes.
| Regression coefficient (95% confidence interval) | |||
|---|---|---|---|
| Systolic blood pressure | Model 1 | 6.425 (0.652–12.197) | 0.029 |
| Model 2 | 6.678 (0.853–12.504) | 0.025 | |
| All three targets attained | Model 1 | −0.500 (−0.780 to −0.219) | 0.001 |
| Model 2 | −0.439 (−0.716 to −0.162) | 0.002 | |
Model 1: adjusted for age, gender, and use of anti-hypertensive drugs.
Model 2: adjusted for age, gender, duration of diabetes, use of anti-diabetic drugs, insulin, lipid lowering drugs, and anti-hypertensive drugs.
*denotes P-value < 0.05.